10% off for first time customers! Use code “daytrypfirst” at checkout.
Ask most people what ketamine treats, and you’ll hear “depression.” Ask the pain research community, and you’ll get a much longer list, one that includes nerve damage, fibromyalgia, and a condition so severe it’s nicknamed “suicide disease.” Here’s what the actual clinical data shows about ketamine’s role in chronic pain, and why the protocol looks nothing like the one built for mood disorders.
Chronic pain isn’t just a signal; it’s a rewiring. Prolonged stimulation of pain pathways leads to upregulation of NMDA receptors in the spinal cord, amplifying pain signals sent to the brain in a process called central sensitization.
Ketamine is the most potent NMDA receptor blocker available for human use, and by interrupting that amplification loop, it addresses one of the core drivers behind neuropathic pain rather than just masking the sensation. That’s a fundamentally different mechanism than opioids, which work on a separate receptor system entirely.
Ketamine has demonstrated significant efficacy in managing neuropathic pain, fibromyalgia, and complex regional pain syndrome, particularly in treatment-resistant cases.
For fibromyalgia specifically, a controlled trial found eight of eleven patients responded to low-dose ketamine infusion, with a significant reduction in pain intensity that in most responders lasted two to seven days past the infusion.
This is where telehealth programs have to get more precise. Depression protocols generally use fixed dosing schedules aimed at mood response. Pain protocols work differently, because current evidence shows ketamine provides significant short-term analgesia, especially for neuropathic pain, but effects are often shorter-lived and require a more individualized maintenance rhythm.
That means dosing frequency, follow-up cadence, and success metrics (pain scale changes, functional improvement, flare frequency) all need separate tracking from a mood-focused program, not a copy-paste of the depression model.
Chronic pain patients have often been left with two options: push through it or manage it with medications that come with their own long list of trade-offs. The NMDA research behind ketamine offers a genuinely different approach: one that targets the nervous system’s amplification of pain rather than just dulling the sensation.
After a full medical evaluation, Daytryp RX’s licensed providers structure home-based ketamine treatment around your specific pain history, with dosing frequency, follow-up cadence, and progress tracking all calibrated for conditions like neuropathic pain, fibromyalgia, and CRPS rather than a generic mood protocol.
Curious whether this approach fits your pain history? Contact us today and let a licensed provider build a protocol around what your nervous system actually needs.
